{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:42:11Z","timestamp":1793155331889,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The amyloidoses are a group of disorders with overlapping clinical presentations, characterized by aggregation and tissue deposition of misfolded proteins. The nature and source of the amyloidogenic protein determines therapy, therefore correct subtyping is critical to patient management. We report the clinicopathologic features of nine patients diagnosed with two amyloid types confirmed by liquid chromatography-coupled tandem mass spectrometry. The most common types were transthyrethin (<jats:italic>n<\/jats:italic>\u2009=\u20099) and immunoglobulin-derived (<jats:italic>n<\/jats:italic>\u2009=\u20097). Two patients did not have immunoglobulin-derived amyloidosis despite the presence of a monoclonal gammopathy. Eight patients were diagnosed with two types concurrently, and one patient had an 11-year interval between diagnoses. Histopathological distribution of amyloid was variable with vascular, interstitial, and periosteal deposits seen. Identification of a second type was incidental in seven patients, but led to genetic counselling in one patient and therapy directed at both amyloid subtypes in another. With longer survival of myeloma and AL amyloidosis patients and increasing prevalence of patients with wild-type transthyretin amyloidosis due to an aging population, the phenomenon of two amyloid types in a single patient will be encountered more frequently. In light of revolutionary new therapies for transthyretin amyloidosis (patisiran, tafamidis, and inotersen), recognition of dual amyloid types is highly clinically relevant.<\/jats:p>","DOI":"10.1038\/s41408-019-0193-9","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T13:02:47Z","timestamp":1551790967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Two types of amyloidosis presenting in a single patient: a case series"],"prefix":"10.1038","volume":"9","author":[{"given":"M. Hasib","family":"Sidiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Theis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surendra","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Vrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Eleni","family":"Drosou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"193_CR1","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini, G., Seldin, D. C. & Gertz, M. A. Amyloidosis: pathogenesis and new therapeutic options. J. Clin. Oncol. 29, 1924\u20131933 (2011).","journal-title":"J. Clin. Oncol."},{"key":"193_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini, G. & Bellotti, V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349, 583\u2013596 (2003).","journal-title":"N. Engl. J. Med."},{"key":"193_CR3","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","volume":"114","author":"JA Vrana","year":"2009","unstructured":"Vrana, J. A. et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 114, 4957\u20134959 (2009).","journal-title":"Blood"},{"key":"193_CR4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"RA Kyle","year":"1992","unstructured":"Kyle, R. A. et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79, 1817\u20131822 (1992).","journal-title":"Blood"},{"key":"193_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","volume":"2","author":"TP Quock","year":"2018","unstructured":"Quock, T. P., Yan, T., Chang, E., Guthrie, S. & Broder, M. S. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2, 1046\u20131053 (2018).","journal-title":"Blood Adv."},{"key":"193_CR6","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann, H. J. et al. Natural history and outcome in systemic AA amyloidosis. N. Engl. J. Med. 356, 2361\u20132371 (2007).","journal-title":"N. Engl. J. Med."},{"key":"193_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/13506129.2018.1449104","volume":"25","author":"T Jhaveri","year":"2018","unstructured":"Jhaveri, T. Once AL amyloidosis: not always AL amyloidosis. Amyloid 25, 139\u2013140 (2018).","journal-title":"Amyloid"},{"key":"193_CR8","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2014-06-580720","volume":"124","author":"S Mahmood","year":"2014","unstructured":"Mahmood, S. et al. Two types of amyloid in a single heart. Blood 124, 3025\u20133027 (2014).","journal-title":"Blood"},{"key":"193_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/j.1365-2133.2007.08432.x","volume":"158","author":"S Koba","year":"2008","unstructured":"Koba, S. et al. The occurrence of two types of amyloid in the same patient. Br. J. Dermatol. 158, 860\u2013862 (2008).","journal-title":"Br. J. Dermatol."},{"key":"193_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5858\/2008-132-14a-UOIFTA","volume":"132","author":"A Solomon","year":"2008","unstructured":"Solomon, A., Murphy, C. L. & Westermark, P. Unreliability of immunohistochemistry for typing amyloid deposits. Arch. Pathol. Lab. Med. 132, 14\u201315 (2008). 14; author reply.","journal-title":"Arch. Pathol. Lab. Med."},{"key":"193_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/00000478-200606000-00002","volume":"30","author":"A Kebbel","year":"2006","unstructured":"Kebbel, A. & Rocken, C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am. J. Surg. Pathol. 30, 673\u2013683 (2006).","journal-title":"Am. J. Surg. Pathol."},{"key":"193_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12014-016-9133-x","volume":"13","author":"P Mollee","year":"2016","unstructured":"Mollee, P. et al. Implementation and evaluation of amyloidosis subtyping by laser-capture microdissection and tandem mass spectrometry. Clin. Proteom. 13, 30 (2016).","journal-title":"Clin. Proteom."},{"key":"193_CR13","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3324\/haematol.2013.102764","volume":"99","author":"JA Vrana","year":"2014","unstructured":"Vrana, J. A. et al. Clinical diagnosis and typing of systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics. Haematologica 99, 1239\u20131247 (2014).","journal-title":"Haematologica"},{"key":"193_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.13156","volume":"168","author":"JD Gillmore","year":"2015","unstructured":"Gillmore, J. D. et al. Guidelines on the diagnosis and investigation of AL amyloidosis. Br. J. Haematol. 168, 207\u2013218 (2015).","journal-title":"Br. J. Haematol."},{"key":"193_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","volume":"6","author":"S Bokhari","year":"2013","unstructured":"Bokhari, S. et al. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ. Cardiovasc. Imaging 6, 195\u2013201 (2013).","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"193_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa, L. J. et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 1, 282\u2013287 (2017).","journal-title":"Blood Adv."},{"key":"193_CR17","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E. et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129, 2111\u20132119 (2017).","journal-title":"Blood"},{"key":"193_CR18","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle, R. A. et al. Prevalence of monoclonal gammopathy of undetermined significance. N. Engl. J. Med. 354, 1362\u20131369 (2006).","journal-title":"N. Engl. J. Med."},{"key":"193_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen, M. et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann. Med. 40, 232\u2013239 (2008).","journal-title":"Ann. Med."},{"key":"193_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho, T., Maurer, M. S. & Suhr, O. B. THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr. Med. Res. Opin. 29, 63\u201376 (2013).","journal-title":"Curr. Med. Res. Opin."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0193-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0193-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T16:11:29Z","timestamp":1671207089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-019-0193-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1038\/s41408-019-0193-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"25 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"30"}}